I am a mathematical biologist and a bioinformatics researcher in the pharmaceutical industry. I received my Ph.D. in Life Science from Hokkaido University in March 2025.
I study biological dynamics using mathematical models and data analysis, with an interest in pharmacometrics and systems biology.
ORCIDGoogle ScholarLinkedInGitHub
A Japanese research note auditing what published phase 1-2 pharmacokinetics, PD-1 receptor occupancy and dose-level response rates can say about 20 versus 10 mg/kg Q3W of ivonescimab, with the analysis plan fixed before computing. The answer is inconclusive. It makes no claim about efficacy ranking, recommended dose or any regulatory decision.
Observed aggregate PK supports a dose-exposure fit. A reconstructed parent PopPK model compares paired regimens in4096 conditional virtual patients. Clinical cohort differences, absorption assumptions and limits of split-dose predictions are explicit.
A Japanese guide comparing purposes, input data, model development, diagnostics and limits of PK/PD, population PK, PBPK and QSP. Three original figures include hypothetical PK/PD dynamics and analytical conditional population distributions. No empirical model estimation or real-drug validation is claimed.